Merck's COVID Pill Doesn't Cut Death Rates in Many Vaxxed Adults
Merck's COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, detailed data from a large study showed.
Stay updated with breaking news from Alacyclovir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck's COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, detailed data from a large study showed.
Drugmaker Pfizer said on Tuesday it is working to improve supply of its COVID-19 antiviral drug Paxlovid in China in order to ensure adequate access to the drug as cases rise in the country.
The US government agreed to pay Pfizer nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral treatment Paxlovid, the company said on Tuesday.
The top 3 things you should know to start your day.
With the last monoclonal antibody treatment de-authorized, experts are focused on existing and new antivirals, new monoclonals, and convalescent plasma (again).